Technology
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Published
1 year agoon
By
USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Dec. 26, 2024 /CNW/ — USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system’s power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively targeting cancer cells while preserving healthy tissue. These innovations underscore the relentless pursuit of breakthroughs in oncology to enhance patient outcomes. Among the key players driving recent progress in the field are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS), Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context Therapeutics Inc. (NASDAQ: CNTX), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
The article continued: The oncology field continues to advance, with MarketsAndMarkets forecasting the Artificial Intelligence in Oncology Market to reach $11.52 billion by 2030, driven by a 29.4% CAGR. Similarly, Nova Advisor predicts the Personalized Cell Therapy Market will grow at a 23.53% CAGR, reaching $251.37 billion by 2034.
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, recently released a recap of major accomplishments from 2024 and a preview of anticipated milestones for the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across its clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities.
“This past year produced highly encouraging clinical developments that we believe set the stage for significant progress, headlined by the robust efficacy results from the BRACELET-1 breast cancer study,” said Wayne Pisano, Interim CEO and Chair of Oncolytics Biotech’s Board of Directors. “In addition, our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field. Key opinion leaders in both breast and GI cancers continue to be excited by pelareorep’s potential as we move into 2025. Based on these insights from leading oncologists, we believe pelareorep has the potential to become a transformational immunotherapy—and that pelareorep-based combination therapies could accelerate our path toward regulatory approval. We are very optimistic about our plans for the next year, and we look forward to showcasing our latest clinical progress early in the new year at the ASCO GI Symposium—an event that could provide key catalysts for our ongoing gastrointestinal cancer programs. Unlike many immunotherapies that struggle to convert ‘cold’ tumors to ‘hot,’ pelareorep’s unique mechanism of action following intravenous delivery has shown the potential to significantly boost patients’ immune responses—making previously unresponsive tumors more susceptible to treatment. I would like to say thank you to our shareholders, clinical collaborators, study sites and their staff, the patients who participate in our trials, and the employees of Oncolytics Biotech who have stepped up in a significant way in the temporary absence of our CEO, Matt Coffey.”
Oncolytics Biotech continues to advance pelareorep, its innovative immunotherapy for multiple cancer indications. Final efficacy results from the BRACELET-1 study in HR+/HER2- metastatic breast cancer demonstrated a median overall survival benefit exceeding one year and a two-year survival rate nearly double that of paclitaxel monotherapy. These findings, supported by earlier IND-213 data, further reinforce pelareorep’s transformative potential. With FDA alignment on a planned registration-enabling study, Oncolytics Biotech aims to offer improved treatment options for approximately 55,000 U.S. patients annually.
Significant progress has also been made in pancreatic cancer, with plans for a registration-enabling study supported by collaborations with the Global Coalition for Adaptive Research (GCAR) and Roche. This follows the GOBLET study’s outcomes, which more than doubled response rates in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. Additionally, the PanCAN-funded GOBLET cohort evaluating pelareorep plus mFOLFIRINOX, with or without atezolizumab, has completed safety run-in enrollment, receiving positive feedback from the Data Safety Monitoring Board. Key findings from this cohort, alongside progress in anal cancer, will be presented at the ASCO GI Symposium in January 2025.
Looking ahead, Oncolytics Biotech will present at the Biotech Showcase on January 13, 2025, and host investor meetings during the J.P. Morgan Healthcare Conference that same week. These events will provide a platform to highlight its clinical advancements and reinforce its commitment to addressing critical unmet needs in oncology.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, recently provided updates on its R&D advancements targeting RAS/MAPK pathway-driven cancers. In October 2024, the company presented promising Phase 1b SEACRAFT-1 data for naporafenib plus trametinib (MEKINIST®), showing potential for an NRAS-mutated melanoma indication and supporting the ongoing Phase 3 SEACRAFT-2 trial. Erasca also announced progress on its pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 programs, confirming best-in-class potential and preparing for IND submissions in 2025. Key milestones include data from SEACRAFT-2 in 2025 and initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in 2026.
“We made significant progress across our pipeline programs and are pleased with the pace of our execution,” said Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca. “Positive preliminary data from SEACRAFT-1, which we reported at the 36th EORTC-NCI-AACR (ENA) Symposium last month, has refined our clinical development focus of naporafenib plus trametinib on patients with NRAS-mutant (NRASm) melanoma, and importantly, heightens our conviction in the ongoing SEACRAFT-2 registrational trial targeting a similar patient population. SEACRAFT-2 has the potential for approval based on the high unmet need of these patients as well as the alignment with US and European regulators on the NRASm melanoma indication. We expect randomized dose optimization data from Stage 1 of this Phase 3 trial in 2025.”
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology company, recently announced new data from the Phase 1 TRAVERSE trial evaluating ALLO-316, its first AlloCAR T™ product candidate, for advanced or metastatic renal cell carcinoma (RCC). Presented at the 2024 IKCS and SITC Annual Meetings, the data demonstrated a 50% overall response rate (ORR) and a 33% confirmed response rate (CRR) in patients with CD70 Tumor Proportion Scores (TPS) ≥50%. ALLO-316 showed robust CAR T cell expansion, manageable safety, and durable tumor responses, supporting the FDA’s RMAT designation for advanced RCC. Additional data from the ongoing Phase 1b expansion cohort is expected in mid-2025.
“ALLO-316, the leading “off-the-shelf” CAR T product candidate currently in development for solid tumors, continues to show remarkable potency in the TRAVERSE trial,” said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer of Allogene. “Data from the Phase 1 study demonstrating significant anti-tumor activity in patients with metastatic disease resistant to multiple therapeutic classes, even with standard lymphodepletion, potentially marks a major advancement in the field. The unprecedented cell expansion and persistence driven by CD70 CAR-intrinsic Dagger® technology, along with strong evidence of tumor infiltration by CAR T cells, highlights the distinctive features of ALLO-316. We believe these findings from our Phase 1 trial lay the groundwork for a new generation of allogeneic cell therapies.”
Context Therapeutics Inc. (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, recently announced advancements in its T cell-engaging bispecific antibody pipeline, including CT-202, a Nectin-4 x CD3 antibody licensed in September 2024, with an IND filing expected in mid-2026. Context also acquired CT-95, a Mesothelin x CD3 antibody, set to begin Phase 1 trials in Q1 2025. Additionally, Context will present data on its Claudin 6-targeting antibody CTIM-76 at the SITC Annual Meeting.
“Context executed on its strategy to build a pipeline of T cell engaging bispecific antibodies through its acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We continue to activate additional sites for our Phase 1 trial for CTIM-76, a Claudin 6 x CD3 bispecific antibody, and expect to dose our first patient by the end of this year. We also expect to advance CT-95 into the clinic soon and expect to enroll our first patient in our CT-95 Phase 1 study in the first quarter of 2025.”
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical stage TechBio company, recently announced interim data from the Phase 1/2 ELUCIDATE trial of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The trial showed REC-617 was well-tolerated with no discontinuations due to adverse events, and one patient with platinum-resistant ovarian cancer achieved a confirmed partial response lasting over six months, while four others had stable disease for up to six months. With plans to continue dose escalation and initiate combination studies in early 2025, REC-617 demonstrates potential as a safe and effective therapy in heavily pre-treated cancer patients.
“Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive cancers,” said David Hallett, Ph.D., Chief Scientific Officer of Recursion. “By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level.”
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.com/news-releases/oncology-in-focus-how-emerging-therapies-are-reshaping-cancer-treatment-302339333.html
SOURCE USA News Group
You may like
Technology
Allegiant Announces Future Board Composition Following Sun Country Acquisition
Published
6 minutes agoon
April 20, 2026By
LAS VEGAS, April 20, 2026 /PRNewswire/ — Allegiant Travel Company (NASDAQ: ALGT) today announced the anticipated structure of its Board of Directors following the acquisition of Sun Country Airlines (NASDAQ: SNCY). Upon closing, the Allegiant Board will expand from eight to eleven members with Jude Bricker, Jennifer Vogel and Thomas Kennedy, all current Sun Country Board members, to join Allegiant’s Board at that time.
In January, Allegiant announced it was acquiring Sun Country in a transaction expected to close as early as May 13, 2026. The combination will form the leading, leisure-focused U.S. airline that is expected to expand affordable, convenient service to more vacation destinations domestically and internationally. After closing, the combined company will operate under the Allegiant name. The airlines will continue operating separately until receiving a single operating certificate from the FAA. There is expected to be no immediate change to ticketing or schedules, and customers can continue to book their flights through allegiant.com and suncountry.com.
“This combination marks a major achievement for both Allegiant and Sun Country, and we look forward to the Allegiant leadership team guiding the company forward,” said Maurice J. Gallagher, Allegiant’s founder and Board Chairman. He added, “The addition of Jude Bricker, Jennifer Vogel, and Thomas Kennedy to our Board reflects the governance structure established for the combined company in the Merger Agreement, and brings to the Allegiant Board even greater expertise in airlines, finance and corporate leadership that will benefit the shareholders, employees and customers of the combined companies.”
Joining the Board upon closing will be:
Jude Bricker has served as President and CEO of Sun Country Airlines since 2017 and has been a Sun Country director since 2018. A seasoned aviation executive with two decades of industry experience, he previously served as Allegiant’s Chief Operating Officer and held multiple leadership roles at Allegiant from 2006–2017, overseeing key commercial, operational, and financial functions. Earlier, he was a finance manager at American Airlines. He also served as an infantry officer in the United States Marine Corps from 1996 to 2002. Mr. Bricker holds a B.S. in Civil Engineering from Texas A&M University and an MBA from the University of Texas, and he is an independent director of SAS Airlines.
Jennifer Vogel has served as Chair of the Sun Country Airlines Board since March 2023 and has been a director since 2022. She is a former senior airline legal and compliance executive, having served as Senior Vice President, General Counsel, Secretary, and Chief Compliance Officer of Continental Airlines (retired 2010). Ms. Vogel currently serves on the boards of AAR Corp. and the Telluride Regional Airport Authority and previously served on the board of Virgin America. She holds a BBA from the University of Iowa and a JD from the University of Texas.
Thomas C. Kennedy has served on the Sun Country Airlines Board since 2021. He is President and CEO, North America at SIXT Rental Car and previously served as its President and CFO. Mr. Kennedy is a former public-company CFO, including as CFO of Hertz Global Holdings, with earlier senior finance leadership roles at Hilton Worldwide and Northwest Airlines. He holds a BA in Economics from Tulane University and an MBA from Harvard University.
“We are excited to welcome these accomplished leaders to Allegiant’s Board upon closing,” said Gregory C. Anderson, CEO of Allegiant. “Their experience and perspective will be valuable as we continue building a stronger, differentiated airline that better serves the communities and customers across our combined network.”
The current Allegiant Board, led by Chairman Maurice J. Gallagher, will continue its oversight responsibilities, with the new members joining effective upon the completion of the Sun Country acquisition.
Strategically, the combination brings together complementary route networks – Allegiant’s focus on small and mid-sized markets and Sun Country’s presence in larger cities – creating more than 650 routes (551 Allegiant routes and 105 Sun Country routes) and connecting Minneapolis–St. Paul to additional mid-sized markets while expanding nonstop access to popular leisure destinations. The combined airline also adds broader international reach by leveraging Sun Country’s service across Mexico, Central America, Canada, and the Caribbean, providing Allegiant customers access to 18 international destinations. The combined company will be headquartered in Las Vegas while maintaining a significant presence in Minneapolis–St. Paul.
About Allegiant – Together We Fly™
Las Vegas-based Allegiant (NASDAQ: ALGT) is an integrated travel company with an airline at its heart, focused on connecting customers with the people, places, and experiences that matter most. Since 1999, Allegiant Air has linked travelers in small-to-medium cities to world-class vacation destinations with all-nonstop flights and industry-low average fares. Today, Allegiant’s fleet serves communities across the nation, with base airfares less than half the cost of the average domestic roundtrip ticket. For more information, visit us at Allegiant.com. Media information, including photos, is available at http://gofly.us/iiFa303wrtF
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and often can be identified by the use of forward-looking terminology such as the words “believe,” “expect,” “guidance,” “anticipate,” “intend,” “plan,” “estimate”, “project”, “hope” or similar expressions. Forward-looking statements in this communication are based on Allegiant’s and Sun Country’s current expectations, estimates and projections about the expected date of closing of the proposed transaction and the potential benefits thereof, their respective businesses and industries, management’s beliefs and certain assumptions made by Allegiant and Sun Country, all of which are subject to change. Forward-looking statements in this communication may relate to, without limitation, the benefits of the proposed transaction, including future financial and operating results; the parties’ respective plans, objectives, expectations and intentions; the expected timing and likelihood of completion of the proposed transaction; expected synergies of the proposed transaction; the timing and result of various regulatory proceedings related to the proposed transaction; the ability to execute and finance current and long-term business, operational, capital expenditures and growth plans and strategies; the impact of increased or increasing transaction and financing costs associated with the proposed transaction or otherwise, as well as inflation and interest rates; and the ability to access debt and equity capital markets.
Forward-looking statements involve risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to, the following: the occurrence of any event, change or other circumstance that could give rise to the right of one or both of the parties to terminate the definitive merger agreement for the proposed transaction; the risk that potential legal proceedings may be instituted against Allegiant or Sun Country and result in significant costs of defense, indemnification or liability; the possibility that the proposed transaction does not close when expected or at all because required stockholder approvals, required regulatory approvals or other conditions to closing are not received or satisfied on a timely basis or at all (and the risk that such regulatory approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction); the risk that the combined company will not realize expected benefits, cost savings, accretion, synergies and/or growth from the proposed transaction or that any of the foregoing may take longer to realize or be more costly to achieve than expected; disruption to the parties’ businesses as a result of the announcement and pendency of the proposed transaction; the costs associated with the anticipated length of time of the pendency of the proposed transaction, including the restrictions contained in the definitive merger agreement on the ability of each of Sun Country and Allegiant to operate their respective businesses outside the ordinary course consistent with past practice during the pendency of the proposed transaction; the diversion of Allegiant’s and Sun Country’s respective management teams’ attention and time from ongoing business operations and opportunities on acquisition-related matters; the risk that the integration of Sun Country’s operations will be materially delayed or will be more costly or difficult than expected or that Allegiant is otherwise unable to successfully integrate Sun Country’s businesses into its businesses; the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; reputational risk and potential adverse reactions of Allegiant’s or Sun Country’s customers, suppliers, employees, labor unions or other business partners, including those resulting from the announcement or completion of the proposed transaction; the dilution caused by Allegiant’s issuance of additional shares of its common stock in connection with the consummation of the proposed transaction; a material adverse change in the business, condition or results of operations of Allegiant or Sun Country; changes in domestic or international economic, political or business conditions, including those impacting the airline industry (including customers, employees and supply chains); Allegiant’s and Sun Country’s ability to successfully implement their respective operational, productivity and strategic initiatives; the outcome of claims, litigation, governmental proceedings and investigations involving Allegiant or Sun Country; and a cybersecurity incident or other disruption to Sun Country’s or Allegiant’s technology infrastructure.
Forward-looking statements in this communication are qualified by and should be read together with, the risk factors set forth above and the risk factors included in Allegiant’s and Sun Country’s respective annual and quarterly reports as filed with the Securities and Exchange Commission (the “SEC”), as well as the risk factors included in Allegiant’s registration statement on Form S-4 (Registration No. 333-294712), as filed with the SEC on March 27, 2026 (https://www.sec.gov/Archives/edgar/data/1362468/000114036126011799/ny20065073x3_s4.htm) (the “Registration Statement”), and readers should refer to such risks, uncertainties and risk factors in evaluating such forward-looking statements.
The forward-looking statements in this communication are made only as of the date they were first issued, and unless otherwise required by applicable securities laws, Allegiant and Sun Country disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Important Additional Information and Where to Find It
In connection with the proposed transaction, Allegiant filed with the SEC the Registration Statement, which includes a prospectus with respect to the shares of Allegiant’s common stock to be issued in the proposed transaction and a joint proxy statement for Allegiant’s and Sun Country’s respective stockholders. The Registration Statement was declared effective on March 31, 2026, and Allegiant filed a final prospectus on March 31, 2026 (which is available at https://www.sec.gov/Archives/edgar/data/1362468/000114036126012380/ny20065073x5_424b3.htm), and Sun Country filed a definitive proxy statement on March 31, 2026 (which is available at https://www.sec.gov/Archives/edgar/data/1743907/000114036126012383/ny20068391x1_defm14a.htm) (together, the “Definitive Joint Proxy Statement/Prospectus”).
Each of Allegiant and Sun Country may also file with or furnish to the SEC other relevant documents regarding the proposed transaction. This communication is not a substitute for the Registration Statement, the Definitive Joint Proxy Statement/Prospectus or any other document that Allegiant or Sun Country may file with the SEC or send to their respective stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF ALLEGIANT AND SUN COUNTRY ARE URGED TO READ THE REGISTRATION STATEMENT AND THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS INCLUDED WITHIN THE REGISTRATION STATEMENT, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE REGISTRATION STATEMENT AND THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING ALLEGIANT, SUN COUNTRY, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders of Allegiant and Sun Country may obtain free copies of these documents and other documents filed with the SEC by Allegiant or Sun Country through the website maintained by the SEC at http://www.sec.gov or from Allegiant at its website, https://ir.allegiantair.com/financials/sec-filings/default.aspx, or from Sun Country at its website, https://ir.suncountry.com/financials/sec-filings. Documents filed with the SEC by Allegiant will be available free of charge by accessing Allegiant’s website at https://ir.allegiantair.com/financials/sec-filings/default.aspx, or alternatively by directing a request by mail to Allegiant’s Investor Relations department, 1201 North Town Center Drive, Las Vegas, NV 89144, and documents filed with the SEC by Sun Country will be available free of charge by accessing Sun Country’s website at https://ir.suncountry.com/financials/sec-filings, or alternatively by directing a request by mail to Sun Country’s Investor Relations department, 2005 Cargo Road, Minneapolis, MN 55450.
Participants In The Solicitation
Allegiant, Sun Country and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Allegiant and Sun Country in connection with the proposed transaction under the rules of the SEC.
Information about the interests of the directors and executive officers of Allegiant and Sun Country and other persons who may be deemed to be participants in the solicitation of stockholders of Allegiant and Sun Country in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, is included in the Definitive Joint Proxy Statement/Prospectus.
Information about the directors and executive officers of Allegiant, their ownership of Allegiant common stock and Allegiant’s transactions with related persons can also be found in the Allegiant Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on March 26, 2026 (the “Allegiant Annual Report”), and other documents subsequently filed by Allegiant with the SEC, which are available on its website, https://ir.allegiantair.com/financials/sec-filings/default.aspx. To the extent holdings of Allegiant common stock by the directors and executive officers of Allegiant have changed from the amounts of Allegiant common stock held by such persons as reflected therein, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=1362468&owner=exclude under the tab “Ownership Disclosures”.
Information about the directors and executive officers of Sun Country, their ownership of Sun Country common stock and Sun Country’s transactions with related persons can also be found in the definitive proxy statement for Sun Country’s 2025 annual meeting of stockholders, as filed with the SEC on Schedule 14A on April 25, 2025 (which is available at https://ir.suncountry.com/financials/sec-filings), and other documents subsequently filed by Sun Country with the SEC. Such information is set forth in the sections entitled “Proposal 1– Reelection of Directors”, “Proposal 2 – Non-binding (Advisory) Vote to Approve the Compensation of Our Named Executive Officers”, “Executive Compensation”, “Certain Relationships and Related Person Transactions” and “Security Ownership of Certain Beneficial Owners and Management” of such definitive proxy statement. Please also refer to Sun Country’s subsequent Current Reports, as filed with the SEC on Form 8-K on September 22, 2025 (which is available at https://ir.suncountry.com/financials/sec-filings) and on October 30, 2025, regarding subsequent changes to Sun Country’s Board of Directors and executive management following the filing of such definitive proxy statement. To the extent holdings of Sun Country common stock by the directors and executive officers of Sun Country have changed from the amounts of Sun Country common stock held by such persons as reflected in the definitive proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=1743907&owner=exclude under the tab “Ownership Disclosures”.
Free copies of these documents may be obtained as described above.
No Offer or Solicitation
This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell, an offer to buy, or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.
Contacts
Allegiant
Media Inquiries: mediarelations@allegiantair.com
Investor Inquiries: ir@allegiantair.com
Sun Country
Media Inquiries:
Wendy Burt
mediarelations@suncountry.com
Investor Relations:
Chris Allen
IR@suncountry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/allegiant-announces-future-board-composition-following-sun-country-acquisition-302747695.html
SOURCE Allegiant Travel Company
Technology
Leidos, Havoc integrate capabilities to advance maritime and air autonomy
Published
6 minutes agoon
April 20, 2026By
Leaders in defense technology combine systems integration and collaborative autonomy to help accelerate operational capability
NATIONAL HARBOR, Md., April 20, 2026 /PRNewswire/ — Leidos (NYSE: LDOS) and Havoc are partnering to integrate unmanned systems with collaborative autonomy technology, enabling a single operator to command and coordinate fleets of platforms across vast, contested areas.
The companies plan to showcase these capabilities during a joint operational validation in the fourth quarter of 2026, where unmanned surface and aerial vehicles are expected to operate under a single autonomy system. The event is intended to provide a clear preview of how collaborative autonomous operations can be executed at scale in real-world conditions.
Elements of Havoc’s collaborative autonomy software will be integrated with Leidos’ Autonomous Vessel Architecture (LAVA) on select platforms, beginning with Sea Archer, the small unmanned surface vessel. This combined approach is designed to enable coordinated operations across systems while seeking to optimize performance, integration speed and cost for specific mission applications. The collaboration aims to define and deliver the architecture for an autonomous battlespace, where distributed systems sense, decide and act together across air, surface and sub-surface domains, even in contested and communications-degraded environments.
“The future of warfare will be defined by how quickly and effectively systems can operate together across domains,” said Leidos Defense President Cindy Gruensfelder. “The Leidos and Havoc team will work to deliver integrated, mission-ready capability that gives commanders more options and operational advantage.”
“Leidos is a strong partner because their vessels and software are proven and trusted,” said Paul Lwin, Co-founder and CEO of Havoc. “By integrating Havoc’s autonomy across those platforms, we expect to compress integration timelines from months to weeks and move systems into production in days, not months. That speed, applied to Leidos’ breadth of platforms, is what makes this partnership so significant for defense customers.”
This partnership combines Leidos’ proven maritime platforms and systems integration expertise with Havoc’s collaborative autonomy capabilities. Depending on the mission, solutions will incorporate Leidos, Havoc, or a combination of both software architectures to deliver scalable capability across existing and future force structures. These systems are designed to operate together to help expand reach, improve coordination and reduce risk to human operators.
About Leidos
Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 50,000 global employees, Leidos reported annual revenues of approximately $17.2 billion for the fiscal year ended January 2, 2026. For more information, visit www.leidos.com.
Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended January 3, 2025, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.
About Havoc
Havoc is the leader in all-domain collaborative autonomy. Its software-defined hardware approach powers military and commercial-grade autonomous systems across sea, air, and land to sense, decide, and act together in complex and contested environments. Havoc connects assets, enabling them to share information, adapt in real time, and continue operating even when communications are disrupted or denied. Havoc optimizes mission performance and minimizes human risk. Havoc was founded in 2024 and is headquartered in Providence, Rhode Island. Learn more at havocai.com.
Media Contacts
Leidos Media Relations
Brandon Ver Velde
(571) 926-1627
brandon.p.vervelde@leidos.com
Havoc Media Relations
media@havocai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leidos-havoc-integrate-capabilities-to-advance-maritime-and-air-autonomy-302747724.html
SOURCE Leidos Holdings, Inc.
Technology
Harmonic Announces Reporting Date for First Quarter 2026 Results
Published
6 minutes agoon
April 20, 2026By
SAN JOSE, Calif., April 20, 2026 /PRNewswire/ — Harmonic (NASDAQ: HLIT) today announced it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Harmonic will host a live webcast to discuss the Company’s results at 2:00 p.m. PT on the same day.
To participate via telephone, please register in advance using this link,
https://register-conf.media-server.com/register/BIc5a3d9e206d54fe09fc0dbcd12efe1cb.
Upon registration, telephone participants will receive a confirmation email detailing how to join the audio version of the webcast, including the dial-in number and a unique registrant ID. The live webcast will be available via Harmonic’s Investor Relations website at https://investor.harmonicinc.com/. The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call.
For those unable to participate in the live event, a replay will be available on the same website after 5:00 p.m. PT.
Further information about Harmonic and the company’s solutions is available at https://www.harmonicinc.com/.
About Harmonic
Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry’s first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet service to consumers’ homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at https://www.harmonicinc.com/.
Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmonic-announces-reporting-date-for-first-quarter-2026-results-302747520.html
SOURCE Harmonic Inc.
Allegiant Announces Future Board Composition Following Sun Country Acquisition
Leidos, Havoc integrate capabilities to advance maritime and air autonomy
Harmonic Announces Reporting Date for First Quarter 2026 Results
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Send Rakhi to UK swiftly with UK Gifts Portal
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology3 days agoInterfaith America Works to Promote Free, Fair and Peaceful Elections
-
Coin Market3 days agoFrench finance minister backs euro-pegged stablecoins to compete with US
-
Near Videos3 days agoWe Have Only Scratched The Surface Of The Agentic Future
-
Technology1 day agoHarmonic Enables DIRECTV to Reimagine Nationwide DTH Service
-
Coin Market3 days agoSingapore Gulf Bank adds stablecoin mint and redeem for 24/7 settlement
-
Near Videos3 days agoAnthropic Cuts Off OpenClaw Subscribers | GPT-Image-2 Leaked | Drift $285M Hack Explained
-
Near Videos3 days agoNEAR Intern Demos the Future of Private Trading
-
Technology3 days agoDynamite Integrates Biometric Cryptography and AI into its Wallet Product
